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There is evidence from randomised-controlled trials that patients with symptomatic hormone-refractory prostate cancer may
experience palliative benefit from chemotherapy with mitoxantrone and prednisone. This treatment is well tolerated, even by elderly
patients, although the cumulative dose of mitoxantrone is limited by cardiotoxicity. Treatment with docetaxel or paclitaxel, with or
without estramustine, appears to convey higher rates of prostate-specific antigen response in phase II trials, but is more toxic. Large
phase III trials comparing docetaxel with mitoxantrone have completed accrual. There is no role for chemotherapy in earlier stages of
disease except in the context of a well-designed clinical trial.
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Chemotherapy has not been shown to alter survival in prostate
cancer. However, in recent years, clinical trials have provided
evidence for a palliative role of chemotherapy in patients with
symptomatic hormone-refractory disease. In addition, new che-
motherapeutic agents have shown promising results in phase II
studies leading to enthusiasm for challenging the belief that
chemotherapy does not alter the natural history of prostate cancer.
In this article, we will review the role of chemotherapy during
various stages of prostate cancer, using hypothetical case reports
to illustrate our evidence-based discussion.
POSSIBLE ROLE OF CHEMOTHERAPY FOR
LOCALISED PROSTATE CANCER
Mr Smith is a healthy 55-year-old male with a strong family history
of prostate cancer. A prostate-specific antigen (PSA) serum test
was included as part of his annual medical examination. The PSA
value was elevated at 22mgl
 1 (normal: o4mgl
 1). Rectal
ultrasound revealed a bulky nodular prostate staged clinically as
T2b and subsequent biopsy showed a Gleason score of 4þ4/10.
Bone and CT scans of the abdomen and pelvis were negative for
metastatic disease. After discussion with an urologist and a
radiation oncologist, Mr Smith decided to proceed with radical
prostatectomy. After searching the internet, he asks his doctors if
use of hormones and/or chemotherapy would decrease the risk of
recurrent disease.
Clinical and pathologic features including the serum level of
PSA, Gleason score and clinical stage can be used to estimate the
probability that a patient will develop recurrent disease after
radical local therapy with surgery or radiation. These factors have
been incorporated into nomograms (Partin et al, 1997; Kattan et al,
1998). Using the Partin nomograms, Mr Smith has a risk of
capsular penetration of about 28%, seminal vesicle involvement of
33% and lymph node involvement of 36%. He also has a
substantial probability of positive margins after radical prosta-
tectomy. According to the Kattan nomogram, Mr Smith has only a
20% (810%) probability of remaining free of disease at 5 years
following radical prostatectomy. High rates of relapse are due both
to local failure and to systemic failure secondary to the presence of
micrometastatic disease. Thus, Mr Smith’s question about
adjuvant therapy is appropriate.
The goals of adjuvant therapy are to destroy residual local and
micrometastatic disease, while tumour burden is low and patient
performance status is good with the intent of curing the patient of
the cancer. When adjuvant therapy is given before the primary
treatment, it is referred to as neoadjuvant therapy. Neoadjuvant
treatment might also decrease the incidence of positive margins in
patients undergoing radical prostatectomy and thereby increase
local control.
Adjuvant hormonal therapy
When systemic therapy is considered in the management of
patients with prostate cancer, hormonal therapy is, in general,
much more effective than cytotoxic chemotherapy. Androgen
ablation (by orchidectomy or luteinising hormone-releasing
hormone (LHRH) agonist, with or without a peripheral antiandro-
gen), is effective in providing a reduction in tumour volume, fall in
PSA and/or relief of clinical symptoms in about 80% of patients
with advanced disease, and the average duration of response is 1–2
years.
For patients with localised T2 prostate cancer, androgen
ablation given 3 months before surgery has been shown to reduce
the stage of disease at surgery and to decrease the rate of positive
margins. However, no differences in biochemical or local
recurrence rates have been demonstrated (Goldenberg et al,
1996; Klotz et al, 1999; Soloway et al, 2002). Criticisms of these
randomised-controlled trials include the short duration of
neoadjuvant treatment, lack of statistical power and lack of long-
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www.bjcancer.comterm follow-up. Two studies have compared adjuvant treatment
with an LHRH agonist to observation after radical prostatectomy.
In the Eastern Cooperative Oncology Group (ECOG) study, 98
patients with node-positive disease found at radical prostatectomy
were randomised to immediate antiandrogen therapy or observa-
tion until disease progression. After a median follow-up of 7 years,
disease progression was reduced and survival was improved
(Messing et al, 1999). In the second study published only in
abstract form, 201 patients with pT3 disease were randomised to
adjuvant goserelin or observation. Patients receiving hormonal
therapy showed an improvement in disease-free survival at a
median follow-up of 5 years (Prayer-Galetti et al, 2000).
There have been several large, well-designed trials of adjuvant
antiandrogen therapy used with radiation therapy (Lawton et al,
2001; Bolla et al, 2002). Within these studies, the duration of
androgen ablation varied from 4 months to indefinite, and
hormonal therapy was initiated at the start of the course of
radiation. Most studies have reported significant improvements in
progression-free survival with the addition of adjuvant hormonal
therapy. A meta-analysis of five randomised clinical trials
involving 42700 patients undertaken by the Radiation Therapy
Oncology Group (RTOG) analysed the impact of androgen
suppression on the disease-specific and overall survival in patients
treated with radiation therapy (Roach et al, 2000). Patients with
high-risk disease, based on clinical stage and Gleason score, were
noted to have about 20% higher survival at 8 years with the
addition of long-term hormonal therapy. Patients with intermedi-
ate risk (bulky or T3 disease) appeared to have better disease-
specific survival at 8 years with the addition of only 4 months of
goserelin and flutamide. These results suggest that subgroups of
patients can be identified who either do not benefit from the use of
hormonal therapy, benefit from short-term hormonal therapy or
who benefit only from long-term hormonal therapy.
Adjuvant chemotherapy
Few studies have investigated the use of chemotherapy as adjuvant
to local therapy for patients with prostate cancer. Most of these
trials have used a combination of androgen ablation and
chemotherapy. While it is logical to include hormonal therapy
because of its greater effectiveness, this may lead to a higher
proportion of noncycling cells and decreased effectiveness of cycle-
active drugs. For patients with breast cancer, a large clinical trial
has shown that sequential treatment with chemotherapy and
tamoxifen gives a superior outcome to concurrent treatment and
this may be relevant to treatment of prostate cancer (Albain et al,
2002).
Experience with neoadjuvant chemotherapy prior to radical
prostatectomy is summarised in Table 1. Pettaway et al (2000)
enrolled 33 patients with high-risk localised prostate cancer to 12
weeks of ketoconazole (a general inhibitor of steroid synthesis)
and doxorubicin alternating with vinblastine, estramustine
(KAVE) and androgen ablation followed by prostatectomy. The
primary objectives were to induce a 20% rate of complete
pathological response in the prostatectomy specimen and to assess
the impact on surgical morbidity. Of the 30 patients who
completed systemic therapy and underwent radical prostatectomy,
there was no detectable increase in the incidence of complications
(33%) as compared to historical controls. However, no patient was
downstaged to pT0 by the systemic treatment. Clark et al treated
18 patients with locally advanced prostate cancer with three cycles
of estramustine and etoposide followed by radical prostatectomy.
At surgery, there was residual disease in all patients, although the
rate of organ-confined disease (31%) was a little higher than
predicted by the Partin nomograms, and only two patients had
positive margins (Clark et al, 2001). In addition, all patients
achieved an undetectable PSA level postoperatively and at a
median follow-up of 14 months. High rates of PSA response to
docetaxel in hormone-refractory prostate cancer (see below) have
led to several ongoing neoadjuvant studies of docetaxel with
and without androgen ablation prior to radical prostatectomy.
(Dreicer and Klein, 2001; Oh et al, 2001; Ko et al, 2002; Hussain
et al, 2003).
The 10-year follow-up data are available for 2 three-arm
randomised clinical trials conducted by the National Prostate
Cancer Project of adjuvant chemotherapy. For patients with
localised disease but at high risk of relapse, patients were
randomised to cyclophosphamide 1gm
 2 every 3 weeks for 2
years, estramustine 600mgm
 2 orally daily for 2 years or
observation, after the investigators choice of definitive therapy
with either surgery (Protocol 900 – 170 evaluable patients) or
radiation (Protocol 1000 – 233 evaluable patients) (Schmidt et al,
1996). No benefit was seen in overall survival, but a significantly
longer median progression-free survival was noted in subgroups of
stage C (surgery protocol) or grade 3 tumours (both radiation and
surgery protocols) following treatment with estramustine. How-
Table 1 Summary of clinical trials of neoadjuvant chemotherapy followed by radical prostatectomy
Author Definition of high-risk group Chemotherapy+androgen ablation N End points/conclusions
Pettaway et al (2000) Clinical stage T1–2, Gleason score X8o r
T2B-2c, Gleason score 7, PSA 410ngml
 1
or clinical stage T3
12w of ketoconazole and doxorubicin
alternating with vinblastine, estramustine
(KAVE)
33 Surgery feasible (30 had RP)
No PT0
10/30 (33%) organ confined disease
20/30 (70%) extracapsular extension
11/30 (37%) positive lymph nodes
5/30 (17%) positive surgical margins
Clark et al (2001) Clinical stage T2b or T3, PSA, PSA
X15ngml
 1 or Gleason scoreX8
Three cycles of estramustine, and oral
etoposide q 4w
16 Surgery feasible
5/16 (31%) organ confined disease
Ko et al (2002) Clinical stage T3 or PSA X20ngml
 1 or
Gleason score X8 or clinical stage T2 with MRI
evidence of seminal vesicle involvement or
Gleason score 4+3 with X5 positive core
biopsies
Four cycles of estramustine and docetaxel
(70mgm
 2) i.v. q 3w
12 Surgery feasible
1/12 (8%) lymph node positive
3/12 (25%) positive surgical margins
Hussain et al (2003) Clinical stage XT2b or PSA X15ngml
 1 or
Gleason score X8
Three to six cycles of estramustine and
docetaxel (70mgm
 2)q3w
21 10 patients had RP (other 11 had RT as
definitive local therapy)
3/10 (30%) positive surgical margins
MRI¼Magnetic resonance imaging; N¼number of patients; PSA¼prostate-specific antigen; q¼every; RP¼radical prostatectomy; w¼week; RT¼radiation therapy.
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as the analysis by subgroup was not planned a priori.I ti s
unclear whether this effect (if real) is related to the estrogenic
(estradiol) and/or alkylating (nitrogen mustard) properties of
estramustine.
Several studies are underway to assess the adjuvant role of
chemotherapy with definitive localised treatment (Gilligan and
Kantoff, 2002). These include the Southwest Oncology Group
(SWOG) 9921 study, in which patients are randomised to androgen
deprivation plus mitoxantrone and prednisone or to androgen
deprivation alone following prostatectoctomy. The RTOG 9902
study is comparing combined androgen blockade with paclitaxel,
etoposide and estramustine chemotherapy after radiation. A third
study will evaluate weekly docetaxel (without androgen ablation)
in high-risk patients postprostatectomy.
Based on the above studies, there is no role for neoadjuvant or
adjuvant chemotherapy combined with either surgery or radiation
for patients with high-risk localised prostate cancer, other than in
the setting of a well-designed clinical trial. Mr Smith should not
receive chemotherapy for management of his disease.
CHEMOTHERAPY IN ASYMPTOMATIC PATIENTS
WITH HORMONE-REFRACTORY PROSTATE CANCER
Mr Smith has a radical prostatectomy. His PSA falls to
undetectable levels, but within 2 years he has biochemical relapse
and he receives local radiation and is started on hormonal therapy.
His PSA falls again to undetectable levels, but 3 years later, his PSA
increases and continues to rise despite continued treatment with
an LHRH agonist and addition and withdrawal of bicalutamide, a
peripheral antiandrogen. Mr Smith now has hormone-refractory
disease and his most recent PSA is 35mgl
 1, with a PSA doubling
time of about 3 months. Bone scan shows several metastatic
lesions, but there is no lymphadenopathy seen on abdominopelvic
CT scan. Mr Smith feels well other than distress from knowing that
his PSA is rising. Would Mr Smith benefit from chemotherapy?
In the past, the results of chemotherapy in patients with prostate
cancer have been disappointing. For example, Yagoda and Petrylak
(1993) reviewed 26 trials of chemotherapy for hormone-refractory
prostate cancer and found a tumour response rate (using a variety
of criteria) of less than 10%. Measuring tumour response in
clinical trials of hormone-refractory prostate cancer has been
problematic as few patients have measurable soft-tissue disease
and the majority of patients have metastases to bone, a location
that is difficult to assess for defining tumour response.
Assessing response of serum PSA can be useful in phase II trials
that evaluate antitumour activity of new drugs. The Prostate-
Specific Antigen Working Group standardised the definition of
PSA response to facilitate comparison between phase II studies
(Bubley et al, 1999). This group suggested that PSA response
require a decline of at least 50% in serum PSA that must be
confirmed by a second PSA value 4 or more weeks later. However,
a decline in serum levels of PSA does not necessarily predict for
clinical benefit, other than in relieving patient distress due to
knowledge of PSA levels. In addition, one must be wary of
comparing phase II studies since outcomes, such as PSA response,
may be as dependent on selection of patients as on the agent under
investigation.
No clinical trial has thus far demonstrated a survival benefit as a
result of using chemotherapy in patients with prostate cancer. As
hormone-refractory prostate cancer is not curable, the goals of
therapy are to make patients live longer or live better. Appropriate
end points for phase III studies are therefore overall survival and
symptom control (or quality of life).
Patients with hormone-refractory prostate cancer are a hetero-
geneous group with respect to age, symptoms, comorbidities and
presence or absence of metastatic disease. Few studies have
focused exclusively on patients with asymptomatic hormone-
refractory prostate cancer.
Mitoxantrone is an anthracycline cytotoxic drug, which inter-
feres with DNA replication. As will be discussed later, mitoxan-
trone and prednisone is used for palliation of symptoms secondary
to advanced cancer. However, Berry et al (2002) randomised 120
men with asymptomatic, hormone-refractory, progressive prostate
cancer to mitoxantrone plus prednisone vs prednisone alone
(Berry et al, 2002). The primary end point of this study was time to
treatment failure, defined by the interval between the date of
starting treatment and occurrence of progressive disease (increase
in size of measurable masses, new soft-tissue lesions or increasing
bone lesions). Secondary end points were PSA response, tumour
response, duration of response and survival. Time to treatment
failure was 8 months in the mitoxantrone and prednisone group
compared to 4 months in the prednisone alone group, but there
was no significant difference in overall survival. However, patients
randomised to prednisone alone are likely to have received
mitoxantrone or other chemotherapy after progression of disease.
Unfortunately, this study did not determine whether early
intervention with chemotherapy in hormone-refractory disease
delayed the onset of symptoms, as there was no assessment of
symptoms or quality of life data other than assessment of toxicity
secondary to chemotherapy, which was minimal.
In summary, there are no data to indicate that an asymptomatic
patient, such as Mr Smith in Scenario 2, would benefit from
chemotherapy. Most trials of patients with hormone-refractory
disease have included a mixture of symptomatic and asymptomatic
patients.
CHEMOTHERAPY IN SYMPTOMATIC PATIENTS
WITH HORMONE-REFRACTORY PROSTATE CANCER
Mr Smith decides to enrol in a clinical trial of a biological
agent. Unfortunately, his PSA continues to rise and he now
begins to experience symptoms of pain in his lower back. MRI
shows metastatic disease in the lumbar spine, but no evidence of
cord compression. He is started on analgesics and bispho-
sphonates and given local radiotherapy to his lumbar spine. His
lower back pain is relieved; however, he still complains of
generalised aches in his bones and is very tired. Is there now a
role for chemotherapy?
The median survival of patients with symptomatic hormone-
refractory prostate cancer is 9–12 months. In later stages of
disease, patients with prostate cancer often experience fatigue,
anorexia, weight loss and pain because of bone metastases.
Radiation therapy can be used to relieve localised bone pain,
but metastases are usually widespread in bone, so that pain is
often experienced in multiple sites. Analgesics and bispho-
sphonates may help with diffuse bone pain, but do not relieve
the constitutional symptoms. Over time patients become increas-
ingly weak and frail. The following agents might be considered in
this situation.
GLUCOCORTICOIDS
Glucocorticoids, primarily dexamethasone and prednisone, can
play a useful role in the management of hormone-refractory
prostate cancer. In symptomatic patients, steroids have been used
to improve appetite, weight loss, fatigue and pain secondary to
bone metastates. In addition, steroids are also important in the
prevention of potential side effects of chemotherapy such as
nausea, vomiting and allergic reactions.
Small phase II studies of glucocorticoid therapy in patients with
progressive prostate cancer after medical or surgical castration
have been reported to show PSA response rates of 40–60% (Storlie
et al, 1995; Saika et al, 2001; Morioka et al, 2002; Akakura et al,
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understood and is thought to involve suppression of adrenal
androgens (Tannock et al, 1989). However, these studies are
difficult to interpret and compare as patient populations are highly
selected, and are heterogeneous in the intensity of previous and
concomitant therapies (Sartor et al, 1998). Many patients involved
in these studies were not truly ‘hormone refractory’ as they did
neither receive adequate treatment with peripheral antiandrogen
therapy nor a trial of antiandrogen withdrawal prior to the
initiation of glucocorticoid therapy. Better assessment of the role
of glutocorticoids alone can be obtained from the larger
randomised phase III trials that included prednisone or hydro-
cortisone alone as a control arm. In these studies, the rate of PSA
response was in the range 16–24%, and generally of short duration
(Tannock et al, 1996; Kantoff et al, 1999; Small et al, 2000b; Berry
et al, 2002). In symptomatic patients, prednisone or hydrocorti-
sone treatment was inferior in improving pain and other
symptoms to arms that included mitoxantrone and steroid. While
higher doses of the more potent glucocorticoid, dexamethasone
might be more effective, another small study found no responses
to 3 weeks of intensive treatment with dexamethasone (Weitzman
et al, 2000).
A trial of low-dose dexamethasone or prednisone appears
reasonable in patients with symptomatic hormone-refractory
prostate cancer who are averse to receiving chemotherapy.
ESTROGENS
Estrogens were used originally as therapy for hormone-sensitive
prostate cancer and provided similar efficacy to orchiectomy.
However, they increase the risk of thromboembolic events and for
this reason estrogens are now used rarely in the treatment of
hormone-sensitive disease. More recently, there is evidence that
some patients with ‘hormone-resistant’ disease (i.e. after primary
androgen ablation and addition and withdrawal of a peripheral
antiandrogen) may have transient responses to estrogens such as
diethylstilbestrol (Farrugia et al, 2000; Orlando et al, 2000). The
mechanism is unknown, but this effect might also account for
responses to the agent PC-SPES, which contains phytoestrogens,
that have been reported for patients with ‘hormone-resistant’
disease (Small et al, 2000a). In view of the potential toxicity of
estrogens in elderly men, they are recommended for use only in
selected patients who have progressed after other types of
treatment.
MITOXANTRONE AND PREDNISONE
Since the goal of treatment was relief of symptoms, a Canadian
group used ‘palliative response’ as the primary end point for their
study of mitoxantrone and prednisone chemotherapy for patients
with hormone-refractory prostate cancer (Tannock et al, 1996). In
all, 161 patients from 11 Canadian institutions were randomised to
receive mitoxantrone (12mgm
 2 every 3 weeks intravenously
(i.v.)) plus prednisone 5mg twice per day or prednisone alone. As
assessed by either a stringent reduction in pain without increase in
the level of analgesic medication or by a 50% reduction in
analgesic medication without increase in pain, the palliative
response rate was greater for patients receiving chemotherapy
(38 vs 21%, P¼0.025). Duration of symptomatic response was also
longer for those on chemotherapy and patients who met the
criterion for palliative response had improvements in most
domains of quality of life, including improvement in overall sense
of well being (Osoba et al, 1999). There was an imperfect
correlation between PSA response and palliative response (Dowl-
ing et al, 2001). These results are consistent with those of a study
by the Cancer and Leukaemia Group B (CALGB), which showed
improved PSA response and pain control with mitoxantrone and
hydrocortisone as compared to hydrocortisone alone (Kantoff et al,
1999). A more recent randomised trial by the Canadian Group has
shown a consistent rate of pain response of 39% to mitoxantrone
and prednisone among 209 patients with pain using similar
criteria, and a 29% PSA response rate, but no significant benefit
from adding the bisphosphonate, clodronate (Ernst et al, 2003).
Mitoxantrone and prednisone are very well tolerated and can be
given to elderly patients. Nausea, vomiting and alopecia are rare,
and myelosuppresion is predictable and rarely a problem.
However, the total dose is limited to about 120mgm
 2 because
of cardiotoxicity at higher doses.
TAXANES AND ESTRAMUSTINE
Docetaxel and paclitaxel are cytotoxic agents that act by stabilising
microtubules, thereby disrupting the cellular microtubule network
that is integral to cell division. Estramustine contains both
estrogenic and alkylating groups and has also been reported to
depolymerise microtubule-associated proteins. Taxanes have been
evaluated in several studies for activity against hormone-refractory
prostate cancer either as single agents or in combination with
estramustine. The rationale for combining taxanes and estramus-
tine is to achieve greater inhibition of microtubule function and
cytotoxicity by binding to different protein targets in the same
microtubular system.
Phase II trials in which patients with hormone-refractory
prostate cancer have been treated with single-agent paclitaxel or
docetaxel are summarised in Table 2. The doses and scheduling of
the taxanes vary between studies, but the end points of PSA
response and response of measurable soft-tissue metastases were
similar; the latter applies to only a minority of the patients enrolled
on these studies. The range of PSA response rates of single-agent
taxanes of 38–46% is greater than the PSA response rate in phase
III studies of mitoxantrone and prednisone (B30%). However, it
can be misleading to make such comparisons as response rates
often fall when an agent moves from the phase II to the phase III
setting. One of the few studies to assess palliative response was
conducted by Beer et al (2001). In this study, palliative response
was seen in 48% of patients and PSA response was achieved in 46%
Table 2 Summary of phase II trials using a single-agent taxane in patients with hormone-refractory prostate cancer
Author Taxane regimen N
Median age
(yrs)
450% PSA
decline
Response in
measurable
disease TTP Survival
Picus and Shultz (1999) Docetaxel 75mgm
 2 q 3wk 35 70 46% 28% (7/25) 9m 27m
Friedland et al (1999) Docetaxel 75mgm
 2 q 3wk 16 69 38% 66% (6/9) NR NR
Berry et al (2001) Docetaxel 36mgm
 2wk
 1 6 of an 8-wk cycle 59 72 41% 33% (2/6) 5.1m 9.4m
Beer et al (2001) Docetaxel 36mgm
 2wk
 1 6 of an 8-wk cycle 24 72 46% 40% (2/5) NR NR
Trivedi et al (2000) Paclitaxel 150mgm
 2wk
 1 18 69 39% 50% (4/8) NR NR
N¼number of patients; NR¼not reported; PSA¼prostate-specific antigen; q¼every; TTP¼time to progression; wk¼week; yrs¼years; q¼every.
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all taxane studies. However, taxanes may also cause neuropathy,
changes in the joints, skin and nails, and fatigue. The use of weekly
taxanes in elderly patients with various tumour types has
demonstrated a more favourable toxicity profile than an every-3
week regimen, while maintaining comparable levels of antitumour
activity.
Phase II clinical trials in which a taxane was combined with
estramustine are summarised in Table 3. The rates of PSA response
in these studies were 45–68%. The risk of thrombosis with a
combination of a taxane and estramustine was higher than
reported for either agent alone and justified the use of antic-
oagulation for prophylaxis of thromboembolic events. It is not
clear whether estramustine is truly enhancing the activity of the
taxane in these trial, or simply adding the season’s responses that
may sometimes be seen with estrogens in this population.
The high PSA response rates observed in taxane-based studies
have led to trials comparing these regimens to the standard of
mitoxantrone and prednisone. In a small randomised study, 130
patients with hormone-refractory prostate cancer received either
of two doses of docetaxel plus estramustine and prednisone or
mitoxantrone and prednisone. Preliminary data suggest a higher
rate of PSA response, and greater clinical benefit, with docetaxel
and estramustine, but this trial is small and has been published
only in abstract form (Oudard et al, 2002).
Two large phase III studies comparing mitoxantrone and
prednisone to docetaxel-based regimens have recently completed
accrual. In the international TAX 327 study, more than 1000
patients were randomised to docetaxel plus prednisone given as
either a 3-weekly or weekly regimen or to mitoxantrone plus
prednisone. End points will include overall survival, PSA response
and palliative response in patients with pain. In the SWOG 9916
study, more than 650 patients with hormone-refractory prostate
cancer were randomised to estramustine and docetaxel or to
mitoxantrone and prednisone. Again the primary end point is
overall survival. Owing to greater toxicity, taxanes should only
replace mitoxantrone as preferred treatment if they have a
substantial effect to improve survival.
In Scenario 3, Mr Smith would have a reasonable probability of
benefit from chemotherapy to improve his symptoms and quality
of life. Mitoxantrone and prednisone are well tolerated and
remains the current standard. There are no data to suggest that Mr
Smith would obtain survival benefit from the introduction of
chemotherapy.
CONCLUSIONS
Numerous studies are underway to assess the role of chemotherapy
for patients with various stages of prostate cancer. Mitoxantrone
and prednisone have been shown to provide palliative benefit to
about 30–40% of patients with symptoms. Results of phase III
studies, which compare this current standard to taxane che-
motherapy for patients with advanced metastatic disease will
become available in 2004. However, even if taxanes with
prednisone or estramustine show an effect to improve survival,
their greater toxicity will require selection of patients with better
performance status to receive them. Use of chemotherapy in the
adjuvant or neoadjuvant setting is experimental and should only
be undertaken in the context of a well-designed clinical trial.
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